A Study of TCD601 in de Novo Renal Transplant Recipients

Overview

About this study

The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

- Able to understand the study requirements and provide written informed consent before
and study assessment is performed

- Male or female patients ≥ 18 to 70 years of age

- Recipients of a de novo renal allograft from a heart-beating deceased, living ABO
compatable, non-HLA identical living related donor

Key Exclusion Criteria:

- Subjects who have received a kidney allograft previously

- Recipient of a kidney from an HLA identical living related donor

- Recipient of a kidney from a donor after cardiac death

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/27/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Andrew Bentall, M.B., Ch.B., M.D.

Open for enrollment

Contact information:

Madeline Engel

(507) 293-2643

Engel.Madeline@mayo.edu

More information

Publications

Publications are currently not available